Trademark: 97623507
Word
REWRITING THE RULES OF DRUG CREATION
Status
Pending
Status Code
686
Status Date
Tuesday, March 26, 2024
Serial Number
97623507
Mark Type
4000
Filing Date
Friday, October 7, 2022
Published for Opposition
Tuesday, March 26, 2024

Trademark Owner History
Cellarity, Inc. - Owner At Publication

Classifications
5 Pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of cancer, autoimmune disorders, transplant rejections, inflammatory disease, immunological disorders, metabolic disorders, neurological disorders, genetic disorders, psychiatric disorders, gastroenterological disorders, renal disorders, cardiovascular disorders, dermatological disorders, respiratory disorders
44 Medical diagnostic and screening services, namely, conducting diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases
42 Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; drug development and discovery; scientific research in the field of drug discovery and development; biomedical research services; pharmaceutical drug development services, namely, preclinical development of therapeutic products; bioinformatic services for scientific research purposes, namely, collecting and analyzing complex biological data through the use of artificial intelligence; providing temporary use of non-downloadable computer software involving the use of artificial intelligence technology for molecular design; scientific diagnostic and screening services, namely, conducting scientific diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases; scientific research, namely, research and analysis services in the fields of artificial intelligence and machine learning analytics and research relating to drug development; providing on-line non-downloadable software for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and transmission of data, images, information and artificial intelligence in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable software featuring machine learning and artificial intelligence for data analysis in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; scientific research, namely, research and analysis services in the scientific fields of artificial intelligence and machine learning analytics, healthcare, biomedical and genomic research; providing on-line non-downloadable software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks

Trademark Events
Mar 26, 2024
Official Gazette Publication Confirmation E-Mailed
Mar 26, 2024
Published For Opposition
Mar 6, 2024
Official Gazette Publication Confirmation E-Mailed
Mar 6, 2024
Notification Of Notice Of Publication E-Mailed
Feb 20, 2024
Approved For Pub - Principal Register
Feb 20, 2024
Examiner's Amendment Entered
Feb 20, 2024
Assigned To Lie
Feb 20, 2024
Notification Of Examiners Amendment E-Mailed
Feb 20, 2024
Examiners Amendment E-Mailed
Feb 20, 2024
Examiners Amendment -Written
Feb 1, 2024
Teas/Email Correspondence Entered
Jan 31, 2024
Correspondence Received In Law Office
Jan 31, 2024
Teas Response To Office Action Received
Nov 3, 2023
Application Extension Granted/Receipt Provided
Nov 3, 2023
Application Extension To Response Period - Received
Aug 4, 2023
Notification Of Non-Final Action E-Mailed
Aug 4, 2023
Non-Final Action E-Mailed
Aug 4, 2023
Non-Final Action Written
Jul 21, 2023
Assigned To Examiner
Apr 6, 2023
Teas Voluntary Amendment Received
Oct 31, 2022
New Application Office Supplied Data Entered

Trademark Alertz updated from USPTO on 2030-01-24